• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medications are not effective. Personalized treatment could be the answer.

Cue is a digital intervention platform that translates passively acquired normal sensor data from smartphones into personalised micro-interventions that improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and reveal distinct characteristics that can be used to predict changes in mood as time passes.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet the majority of people with the condition receive treatment. To improve outcomes, clinicians must be able to identify and treat patients most likely to benefit from certain treatments.

The ability to tailor depression treatments for depression is one method of doing this. By using sensors on mobile phones as well as an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from the treatments they receive. With two grants totaling more than $10 million, they will use these technologies to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research to so far has focused on sociodemographic and clinical characteristics. These include demographics such as age, gender and education as well as clinical characteristics like severity of symptom and comorbidities as well as biological markers.

Few studies have used longitudinal data in order to determine mood among individuals. Few studies also take into consideration the fact that moods can be very different between individuals. Therefore, it is crucial to create methods that allow the recognition of the individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to detect patterns of behavior and emotions that are unique to each individual.

The team also developed a machine learning algorithm to model dynamic predictors for each person's depression mood. The algorithm integrates the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype was linked to CAT DI scores which is a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of Symptoms

Depression is one of the most prevalent causes of disability1 but is often not properly diagnosed and treated. Depression disorders are rarely treated due to the stigma that surrounds them and the absence of effective treatments.

To help with personalized treatment, it is crucial to identify predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which are not reliable and only identify a handful of features associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes capture a large number of distinct behaviors and activities, which are difficult to document through interviews, and allow for continuous and high-resolution measurements.

The study involved University of California Los Angeles students with moderate to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or to clinical treatment according to the degree of their depression. Participants with a CAT-DI score of 35 65 students were assigned online support by the help of a coach. Those with scores of 75 patients were referred to psychotherapy in-person.

At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial features. The questions asked included age, sex and education, financial status, marital status and whether they were divorced or not, their current suicidal thoughts, intent or attempts, as well as how often they drank. Participants also rated their degree of depression symptom severity on a 0-100 scale using the CAT-DI. The CAT-DI assessment was conducted every two weeks for those who received online support, and weekly for those who received in-person care.

Predictors of Treatment Response

Research is focusing on personalized residential treatment for depression (Click Link) for depression. Many studies are focused on finding predictors that can help doctors determine the most effective drugs to treat each patient. Particularly, pharmacogenetics is able to identify genetic variations that affect the way that the body processes antidepressants. This allows doctors to select drugs that are likely to be most effective for each patient, while minimizing the time and effort involved in trial-and-error procedures and avoid any adverse effects that could otherwise hinder the progress of the patient.

Another approach that is promising is to build models for prediction using multiple data sources, combining clinical information and neural imaging data. These models can be used to identify which variables are the most predictive of a specific outcome, like whether a drug will help with symptoms or mood. These models can be used to predict the patient's response to a treatment, allowing doctors to maximize the effectiveness.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been proven to be useful in predicting treatment outcomes such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and will likely be the norm in future clinical practice.

Research into the underlying causes of depression continues, as well as ML-based predictive models. Recent findings suggest that depression is linked to the malfunctions of certain neural networks. This suggests that an individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

One method of doing this is through internet-delivered interventions that can provide a more personalized and customized experience for patients. One study found that a web-based program was more effective than standard treatment in reducing symptoms and ensuring the best quality of life for people with MDD. A controlled study that was randomized to an individualized treatment for depression found that a significant percentage of patients saw improvement over time as well as fewer side effects.

Predictors of adverse effects

In the treatment of depression, a major challenge is predicting and identifying which antidepressant medications will have very little or no negative side negative effects. Many patients experience a trial-and-error approach, using several medications prescribed before finding one that is safe and effective. Pharmacogenetics provides an exciting new way to take an efficient and specific approach to choosing antidepressant medications.

A variety of predictors are available to determine which antidepressant is best to prescribe, including gene variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and co-morbidities. However, identifying the most reliable and accurate predictive factors for a specific treatment is likely to require randomized controlled trials of significantly larger numbers of participants than those typically enrolled in clinical trials. This is because it may be more difficult to determine interactions or moderators in trials that only include one episode per person instead of multiple episodes over a long period of time.

In addition the prediction of a patient's response will likely require information on comorbidities, symptom profiles and the patient's subjective experience of tolerability and effectiveness. Currently, only a few easily identifiable sociodemographic variables and clinical variables are reliable in predicting the response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics in the treatment of depression. First it is necessary to have a clear understanding of the genetic mechanisms is essential, as is a clear definition of what treatments are available for depression constitutes a reliable predictor for treatment response. Ethics like privacy, and the responsible use genetic information must also be considered. The use of pharmacogenetics may, in the long run help reduce stigma around mental health treatment and improve the quality of treatment. As with any psychiatric approach it is crucial to give careful consideration and implement the plan. The best option is to offer patients a variety of effective medications for depression and encourage them to talk freely with their doctors about their concerns and experiences.